Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEED: Empagliflozin in Patients Initiating Hemodialysis for ESRD
NCT05786443Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Change in Extracellular Volume at 12 weeks, Change in Intracellular Volume at 12 weeks and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT05786443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786443.